{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T04:17:38Z","timestamp":1795234658843,"version":"4.10.3"},"reference-count":133,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>All cases of multiple myeloma (MM) are preceded by precursor states termed monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). Genetic analyses of MGUS cells have provided evidence that it is a genetically advanced lesion, wherein tumor cells carry many of the genetic changes found in MM cells. Intraclonal heterogeneity is also established early during the MGUS phase. Although the genetic features of MGUS or SMM cells at baseline may predict disease risk, transition to MM involves altered growth of preexisting clones. Recent advances in mouse modeling of MGUS suggest that the clinical dormancy of the clone may be regulated in part by growth controls extrinsic to the tumor cells. Interactions of MGUS cells with immune cells, bone cells, and others in the bone marrow niche may be key regulators of malignant transformation. These interactions involve a bidirectional crosstalk leading to both growth-supporting and inhibitory signals. Because MGUS is already a genetically complex lesion, application of new tools for earlier detection should allow delineation of earlier stages, which we term as pre-MGUS. Analyses of populations at increased risk of MGUS also suggest the possible existence of a polyclonal phase preceding the development of MGUS. Monoclonal gammopathy in several patients may have potential clinical significance in spite of low risk of malignancy. Understanding the entire spectrum of these disorders may have broader implications beyond prevention of clinical malignancy.<\/jats:p>","DOI":"10.1182\/blood-2016-09-692954","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T23:05:53Z","timestamp":1476399953000},"page":"2599-2606","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":154,"title":["MGUS to myeloma: a mysterious gammopathy of underexplored significance"],"prefix":"10.1182","volume":"128","author":[{"given":"Madhav V.","family":"Dhodapkar","sequence":"first","affiliation":[{"name":"Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111903463511000_B1","first-page":"211","article-title":"Studies on conditions associated with disturbed gamma globulin formation (gammopathies)","volume":"56","author":"Waldenstrom","year":"1960-1961","journal-title":"Harvey Lect"},{"issue":"5","key":"2019111903463511000_B2","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"issue":"24","key":"2019111903463511000_B3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"9727","key":"2019111903463511000_B4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"2019111903463511000_B5","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111903463511000_B6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111903463511000_B7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111903463511000_B8","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111903463511000_B9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111903463511000_B10","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111903463511000_B11","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111903463511000_B12","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-10-1822","article-title":"From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention","volume":"17","author":"Landgren","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111903463511000_B13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica"},{"issue":"22","key":"2019111903463511000_B14","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111903463511000_B15","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111903463511000_B16","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3324\/haematol.2014.107938","article-title":"Early lymphoid lesions: conceptual, diagnostic and clinical challenges","volume":"99","author":"Ganapathi","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2019111903463511000_B17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111903463511000_B18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2019111903463511000_B19","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111903463511000_B20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"7339","key":"2019111903463511000_B21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"2019111903463511000_B22","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"5","key":"2019111903463511000_B23","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/leu.2014.321","article-title":"Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential","volume":"29","author":"Pa\u00edno","year":"2015","journal-title":"Leukemia"},{"issue":"6282","key":"2019111903463511000_B24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"issue":"4","key":"2019111903463511000_B25","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"2019111903463511000_B26","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2019111903463511000_B27","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.leu.2403518","article-title":"Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma","volume":"18","author":"Kaufmann","year":"2004","journal-title":"Leukemia"},{"issue":"7","key":"2019111903463511000_B28","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","article-title":"The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells","volume":"17","author":"L\u00f3pez-Corral","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111903463511000_B29","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/leu.2012.128","article-title":"SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status","volume":"26","author":"Lopez-Corral","year":"2012","journal-title":"Leukemia."},{"key":"2019111903463511000_B30","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.12774","article-title":"Genome-wide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance","author":"Mikulasova","year":"2016","journal-title":"Eur J Haematol"},{"issue":"5","key":"2019111903463511000_B31","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2019111903463511000_B32","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2019111903463511000_B33","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"34","key":"2019111903463511000_B34","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111903463511000_B35","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3324\/haematol.2015.124651","article-title":"Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)","volume":"100","author":"Khan","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2019111903463511000_B36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111903463511000_B37","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"2019111903463511000_B38","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3324\/haematol.2013.087809","article-title":"Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies","volume":"99","author":"L\u00f3pez-Corral","year":"2014","journal-title":"Haematologica"},{"key":"2019111903463511000_B39","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1038\/bcj.2016.19","article-title":"Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)","volume":"6","author":"Papanikolaou","year":"2016","journal-title":"Blood Cancer J"},{"issue":"4","key":"2019111903463511000_B40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ccr.2010.09.005","article-title":"Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53\/MDM2 autoregulatory loop in multiple myeloma development","volume":"18","author":"Pichiorri","year":"2010","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111903463511000_B41","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1101\/gr.180240.114","article-title":"Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers","volume":"25","author":"Agirre","year":"2015","journal-title":"Genome Res"},{"issue":"8","key":"2019111903463511000_B42","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/leu.2014.13","article-title":"Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma","volume":"28","author":"Melchor","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2019111903463511000_B43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MOH.0000000000000049","article-title":"Common progenitor cells in mature B-cell malignancies: implications for therapy","volume":"21","author":"Green","year":"2014","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"2019111903463511000_B44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"2019111903463511000_B45","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/leu.2014.59","article-title":"Serial exome analysis of disease progression in premalignant gammopathies","volume":"28","author":"Zhao","year":"2014","journal-title":"Leukemia"},{"key":"2019111903463511000_B46","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice","volume-title":"Nat Med","author":"Das","year":"2016"},{"key":"2019111903463511000_B47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-032712-095921","article-title":"Human hemato-lymphoid system mice: current use and future potential for medicine","volume":"31","author":"Rongvaux","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2019111903463511000_B48","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol Rev"},{"issue":"8","key":"2019111903463511000_B49","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1084\/jem.20052136","article-title":"Enhancement of clonogenicity of human multiple myeloma by dendritic cells","volume":"203","author":"Kukreja","year":"2006","journal-title":"J Exp Med"},{"issue":"1","key":"2019111903463511000_B50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2141.2006.06369.x","article-title":"Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications","volume":"136","author":"Kukreja","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111903463511000_B51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"issue":"11","key":"2019111903463511000_B52","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1182\/blood-2006-03-012542","article-title":"CD28-mediated regulation of multiple myeloma cell proliferation and survival","volume":"109","author":"Bahlis","year":"2007","journal-title":"Blood"},{"issue":"16","key":"2019111903463511000_B53","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2009-03-211920","article-title":"Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease","volume":"114","author":"Kukreja","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111903463511000_B54","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.exphem.2011.04.006","article-title":"Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro","volume":"39","author":"Tucci","year":"2011","journal-title":"Exp Hematol"},{"issue":"10","key":"2019111903463511000_B55","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2011-08-376236","article-title":"Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma","volume":"119","author":"Koduru","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111903463511000_B56","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nri3447","article-title":"The good, the bad and the ugly - TFH cells in human health and disease","volume":"13","author":"Tangye","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2019111903463511000_B57","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.4049\/jimmunol.1201363","article-title":"Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment","volume":"190","author":"Rawal","year":"2013","journal-title":"J Immunol"},{"issue":"5","key":"2019111903463511000_B58","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00262-004-0607-8","article-title":"Harnessing host immune responses to preneoplasia: promise and challenges","volume":"54","author":"Dhodapkar","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"2019111903463511000_B59","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"issue":"4","key":"2019111903463511000_B60","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.20062387","article-title":"Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy","volume":"204","author":"Spisek","year":"2007","journal-title":"J Exp Med"},{"issue":"22","key":"2019111903463511000_B61","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111903463511000_B62","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"issue":"20","key":"2019111903463511000_B63","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1073\/pnas.202491499","article-title":"T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells","volume":"99","author":"Dhodapkar","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019111903463511000_B64","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-04-3337","article-title":"Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors","volume":"65","author":"Noonan","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"2019111903463511000_B65","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0711293105","article-title":"MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2019111903463511000_B66","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","article-title":"In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma","volume":"107","author":"Beyer","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111903463511000_B67","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T regulatory cells in multiple myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"issue":"15","key":"2019111903463511000_B68","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111903463511000_B69","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J Exp Med"},{"issue":"6","key":"2019111903463511000_B70","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-3083.2010.02463.x","article-title":"Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR\u207b\/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma","volume":"72","author":"Brimnes","year":"2010","journal-title":"Scand J Immunol"},{"issue":"26","key":"2019111903463511000_B71","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"issue":"18","key":"2019111903463511000_B72","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","article-title":"A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111903463511000_B73","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111903463511000_B74","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2019111903463511000_B75","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1172\/JCI77181","article-title":"Immunosurveillance and therapy of multiple myeloma are CD226 dependent","volume":"125","author":"Guillerey","year":"2015","journal-title":"J Clin Invest"},{"issue":"8","key":"2019111903463511000_B76","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"issue":"22","key":"2019111903463511000_B77","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1158\/0008-5472.CAN-15-1320","article-title":"Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment","volume":"75","author":"Ponzetta","year":"2015","journal-title":"Cancer Res"},{"issue":"18","key":"2019111903463511000_B78","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"El-Sherbiny","year":"2007","journal-title":"Cancer Res"},{"issue":"1","key":"2019111903463511000_B79","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"issue":"15","key":"2019111903463511000_B80","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111903463511000_B81","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2141.2002.03879.x","article-title":"Anti-myeloma activity of natural killer lymphocytes","volume":"119","author":"Frohn","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111903463511000_B82","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2010.12.010","article-title":"Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges","volume":"140","author":"Dhodapkar","year":"2011","journal-title":"Clin Immunol"},{"issue":"4","key":"2019111903463511000_B83","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood-2008-04-149831","article-title":"Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer","volume":"112","author":"Chang","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111903463511000_B84","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2014-09-600270","article-title":"Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation","volume":"125","author":"Nair","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111903463511000_B85","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood-2012-06-435503","article-title":"Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma","volume":"121","author":"Richter","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111903463511000_B86","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Spanoudakis","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111903463511000_B87","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12307-011-0086-3","article-title":"The immune microenvironment of myeloma","volume":"4","author":"Noonan","year":"2011","journal-title":"Cancer Microenviron"},{"issue":"8","key":"2019111903463511000_B88","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-016-2135-z","article-title":"Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies","volume":"73","author":"Guillerey","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2019111903463511000_B89","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","article-title":"Myeloma as a model for the process of metastasis: implications for therapy","volume":"120","author":"Ghobrial","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111903463511000_B90","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","article-title":"CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation","volume":"12","author":"Roccaro","year":"2015","journal-title":"Cell Reports"},{"issue":"1","key":"2019111903463511000_B91","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.celrep.2014.08.042","article-title":"SDF-1 inhibition targets the bone marrow niche for cancer therapy","volume":"9","author":"Roccaro","year":"2014","journal-title":"Cell Reports"},{"issue":"25","key":"2019111903463511000_B92","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1182\/blood-2011-04-351437","article-title":"Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1\u03b1 levels in patients with MGUS","volume":"118","author":"Ng","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111903463511000_B93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019111903463511000_B94","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"issue":"11","key":"2019111903463511000_B95","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies","volume":"87","author":"Bataille","year":"1996","journal-title":"Blood"},{"issue":"2","key":"2019111903463511000_B96","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: Pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J Bone Oncol"},{"issue":"13","key":"2019111903463511000_B97","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"issue":"11","key":"2019111903463511000_B98","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2019111903463511000_B99","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the microenvironment: myeloma-osteoclast interactions as a model","volume":"64","author":"Yaccoby","year":"2004","journal-title":"Cancer Res"},{"issue":"26","key":"2019111903463511000_B100","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111903463511000_B101","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111903463511000_B102","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/leu.2012.126","article-title":"Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway","volume":"26","author":"Xu","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111903463511000_B103","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood-2008-03-145169","article-title":"The role of Dickkopf-1 in bone development, homeostasis, and disease","volume":"113","author":"Pinzone","year":"2009","journal-title":"Blood"},{"key":"2019111903463511000_B104","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"issue":"11","key":"2019111903463511000_B105","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/leu.2009.130","article-title":"Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma","volume":"23","author":"Roussou","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"2019111903463511000_B106","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/jbmr.2387","article-title":"unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?","volume":"29","author":"Drake","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2019111903463511000_B107","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood.V90.9.3743","article-title":"Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen","volume":"90","author":"Pecherstorfer","year":"1997","journal-title":"Blood"},{"issue":"10","key":"2019111903463511000_B108","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/leu.2010.173","article-title":"The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"2019111903463511000_B109","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood-2013-08-524025","article-title":"Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells","volume":"123","author":"Tanno","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111903463511000_B110","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111903463511000_B111","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111903463511000_B112","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/leu.2016.3","article-title":"Targeting vasculogenesis to prevent progression in multiple myeloma","volume":"30","author":"Moschetta","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"2019111903463511000_B113","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2002-09-2825","article-title":"Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma","volume":"101","author":"Zojer","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111903463511000_B114","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.cell.2008.09.062","article-title":"AID is required for the chromosomal breaks in c-myc that lead to c-myc\/IgH translocations","volume":"135","author":"Robbiani","year":"2008","journal-title":"Cell"},{"key":"2019111903463511000_B115","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"7463","key":"2019111903463511000_B116","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"15","key":"2019111903463511000_B117","doi-asserted-by":"crossref","first-page":"13229","DOI":"10.18632\/oncotarget.3644","article-title":"Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma","volume":"6","author":"Cowan","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"2019111903463511000_B118","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ng.3214","article-title":"A Big Bang model of human colorectal tumor growth","volume":"47","author":"Sottoriva","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"2019111903463511000_B119","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/2159-8290.CD-15-0439","article-title":"Evolutionary determinants of cancer","volume":"5","author":"Greaves","year":"2015","journal-title":"Cancer Discov"},{"issue":"10","key":"2019111903463511000_B120","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin Chem"},{"key":"2019111903463511000_B121","author":"Das"},{"issue":"3","key":"2019111903463511000_B122","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","article-title":"Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism","volume":"18","author":"Mistry","year":"2013","journal-title":"Crit Rev Oncog"},{"issue":"6","key":"2019111903463511000_B123","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111903463511000_B124","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4452","article-title":"Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy","volume":"235","author":"Pavlova","year":"2015","journal-title":"J Pathol"},{"issue":"12","key":"2019111903463511000_B125","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"2019111903463511000_B126","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ajh.22040","article-title":"High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa","volume":"86","author":"Buadi","year":"2011","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111903463511000_B127","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","article-title":"Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111903463511000_B128","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamaoncol.2015.2938","article-title":"Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study","volume":"1","author":"Landgren","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"2019111903463511000_B129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/leu.2014.295","article-title":"Diet-induced obesity promotes a myeloma-like condition in vivo","volume":"29","author":"Lwin","year":"2015","journal-title":"Leukemia"},{"issue":"13","key":"2019111903463511000_B130","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111903463511000_B131","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","article-title":"Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"2019111903463511000_B132","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2141.2001.02533.x","article-title":"Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance","volume":"112","author":"Gregersen","year":"2001","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111903463511000_B133","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/23\/2599\/1396763\/blood692954.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/23\/2599\/1396763\/blood692954.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:47:25Z","timestamp":1574135245000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/23\/2599\/35646\/MGUS-to-myeloma-a-mysterious-gammopathy-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,8]]},"references-count":133,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-692954","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,8]]}}}